Santen Pharmaceutical Co (4536) AI Stock Analysis

• Market Cap: ¥562.76B
• Dividend Yield: 2.3%
• Average Volume (3M): 1.30M
• Price to Earnings (P/E): 19.0
• Beta (1Y): 0.36
• Revenue Growth: -3.66%
• EPS Growth: 25.93%
• Country: JP
• Employees: 3,744
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - General
• EPS (TTM): 24.40
• Shares Outstanding: 322,273,960
• 10 Day Avg. Volume: 1,416,570
• 30 Day Avg. Volume: 1,302,203
• PEG Ratio: 0.32
• Price to Book (P/B): 1.73
• Price to Sales (P/S): 1.65
• P/FCF Ratio: 9.11
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): 100.06
• Revenue Forecast (FY): ¥291.19B

• Rating: 72 Outperform
• Price Target: ¥1,908.00 ▲(19.47% Upside)
• Action: Reiterated Date: 02/07/26
• Date: Action: Reiterated 02/07/26

The score is driven primarily by solid financial health and recovering profitability supported by low leverage, partially offset by declining revenue and a recent weakening in TTM cash flow. Technicals are neutral-to-constructive with longer-term trend support but limited near-term momentum, while valuation appears fair rather than compelling.

Positive Factors

Conservative balance sheet

Very low leverage and a large equity base provide durable financial flexibility to fund R&D, support launches, and withstand temporary revenue softness. This conservative capital structure reduces refinancing risk and preserves optionality for strategic investments over the next several quarters.

Rebound to profitable margins

A return to consistent profitability and double-digit net margins indicates the company has restored earnings power after 2023. Sustainable margins reflect durable cost control and pricing on core ophthalmic products, supporting free cash generation and reinvestment capacity over the medium term.

Specialized ophthalmology franchise & global reach

A focused ophthalmology business and established branded franchises create competitive advantages in product expertise, physician relationships, and lifecycle management. Geographic presence beyond Japan supports diversified revenue streams and allows label expansions and rollouts to extend product life cycles sustainably.

Negative Factors

Declining revenue trend

Ongoing revenue declines reduce operating leverage and can erode long-term growth potential if not reversed. Persistent top-line weakness pressures margins, limits reinvestment capacity, and raises execution risk for product launches and lifecycle extensions over the next several quarters.

Weakening cash flow momentum

A step-down in operating and free cash flow signals higher working-capital needs or elevated investment spending, reducing excess liquidity. Weaker cash conversion constrains funding for R&D, marketing, or dividends and lowers resilience to prolonged sales softness over 2–6 months.

Exposure to Japan pricing/regulatory risk

Heavy exposure to Japan's regulated reimbursement framework creates a structural sensitivity to price revisions and policy changes. Because domestic sales drive core revenue, adverse pricing or reimbursement decisions could materially pressure top-line durability and margin sustainability over the medium term.

Santen Pharmaceutical Co Business Overview & Revenue Model

Company Description

Santen Pharmaceutical Co., Ltd. (Ticker: 4536) is a global pharmaceutical company headquartered in Japan, specializing in the research, development, manufacturing, and marketing of products primarily for ophthalmology. Established in 1890, Santen focuses on innovative treatments for various eye diseases and conditions, including glaucoma, retinal disorders, and dry eye disease. The company operates in multiple sectors, including prescription pharmaceuticals, over-the-counter (OTC) products, and medical devices, aiming to improve the quality of life for patients worldwide.

How the Company Makes Money

Santen Pharmaceutical generates revenue through several key streams: the sale of prescription drugs, especially those targeting ophthalmic conditions, contributes significantly to its earnings. The company has a robust product portfolio that includes well-established brands and newly launched therapies. Additionally, Santen engages in partnerships and collaborations with other pharmaceutical companies, which can include co-development agreements and licensing deals, enhancing its market presence and generating upfront and milestone payments. The company's ongoing investment in research and development also positions it to innovate and expand its product offerings, ensuring continued revenue growth. International markets play a vital role in Santen's earnings, as the company is strategically expanding its reach beyond Japan, tapping into emerging markets and established healthcare systems alike.

Santen Pharmaceutical Co Financial Statement Overview

Summary

Strong balance sheet with low leverage and improving profitability after the 2023 loss year, but revenue is declining and TTM operating/free cash flow has stepped down, which raises execution risk if sales softness persists.

Income Statement

Profitability is solid in TTM (Trailing-Twelve-Months), with healthy gross and operating margins and a net margin a bit above 10%. Results also show a clear rebound from the 2023 annual loss to consistent profitability in 2024–2025. The main weakness is growth: revenue is slightly down in the latest annual period and declined more sharply in TTM (Trailing-Twelve-Months), suggesting demand or pricing headwinds despite good cost control.

Balance Sheet

The balance sheet looks conservative, with low leverage (debt-to-equity roughly ~0.10–0.13 across periods) and a large equity base supporting assets. Returns on equity are positive again in 2024–TTM (Trailing-Twelve-Months) after the 2023 loss year, indicating improving earnings power. A key risk is that equity and total assets have trended down from 2022 levels, which could limit flexibility if the revenue softness persists.

Cash Flow

Cash generation is generally positive, with free cash flow remaining strong and closely tracking net income (free cash flow running at ~85–89% of net income in 2024–TTM). However, cash flow momentum has weakened recently: operating cash flow dropped notably in TTM (Trailing-Twelve-Months) versus the latest annual period and free cash flow is declining in TTM, pointing to higher working-capital needs and/or elevated investment spending.

Breakdown	TTM	Mar 2026	Mar 2025	Mar 2024	Mar 2023	Mar 2022
Income Statement
Total Revenue	287.99B	300.00B	301.96B	279.04B	266.26B	249.60B
Gross Profit	157.20B	171.03B	178.71B	166.09B	156.59B	151.38B
EBITDA	61.39B	68.83B	56.46B	14.30B	54.52B	30.01B
Net Income	30.60B	36.25B	26.64B	-14.95B	27.22B	9.31B
Balance Sheet
Total Assets	401.16B	409.28B	435.70B	421.18B	459.98B	405.29B
Cash, Cash Equivalents and Short-Term Investments	61.54B	93.00B	94.96B	58.68B	84.31B	63.41B
Total Debt	36.15B	34.23B	35.16B	36.21B	32.93B	10.15B
Total Liabilities	118.72B	124.10B	130.33B	127.88B	123.13B	95.30B
Stockholders Equity	283.38B	286.24B	306.06B	293.98B	337.49B	310.18B
Cash Flow
Free Cash Flow	35.53B	54.27B	61.96B	12.56B	10.20B	15.00B
Operating Cash Flow	41.41B	60.93B	72.65B	37.15B	46.04B	38.81B
Investing Cash Flow	-12.59B	-8.22B	-6.14B	-26.78B	-35.17B	-53.35B
Financing Cash Flow	-48.70B	-53.31B	-34.03B	-37.22B	5.56B	-16.68B

Santen Pharmaceutical Co Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 1597.00
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4536, the sentiment is Positive. The current price of 1597 is below the 20-day moving average (MA) of 1731.85, below the 50-day MA of 1705.93, and below the 200-day MA of 1619.14, indicating a bullish trend. The MACD of 7.90 indicates Negative momentum. The RSI at 57.17 is Neutral, neither overbought nor oversold. The STOCH value of 79.92 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:4536.

Santen Pharmaceutical Co Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
5889	79 Outperform	¥48.22B	11.41	―	3.22%	12.92%	29.48%
4503	75 Outperform	¥4.68T	14.43	7.97%	3.61%	13.24%	127.88%
7780	74 Outperform	¥144.55B	20.75	5.97%	1.78%	3.17%	7.07%
4536	72 Outperform	¥562.76B	19.02	10.89%	2.30%	-3.66%	25.93%
8086	62 Neutral	¥259.41B	17.06	4.38%	2.03%	6.04%	733.13%
4890	57 Neutral	¥7.07B	-17.71	―	―	-12.40%	43.42%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Santen Pharmaceutical Co Corporate Events

Santen Pharmaceutical Posts Lower Nine-Month Earnings but Raises Annual Dividend and Maintains Outlook

Santen Pharmaceutical reported weaker consolidated results for the nine months ended December 31, 2025, with revenue declining 5.4% year on year to ¥210.8 billion and core operating profit dropping 20.3%, reflecting profit pressure despite a still-solid earnings base. Net profit attributable to owners of the company fell 20.6%, although total comprehensive income rose 54.9%, and the balance sheet remained strong with an equity ratio above 70%. The company kept its full-year forecast for the fiscal year ending March 31, 2026 unchanged, projecting slight declines in revenue and profit versus the previous year, and confirmed an increase in annual dividends from ¥36 to ¥38 per share, signaling continued shareholder returns even as operating performance softens. Santen also cancelled a portion of its treasury shares in November 2025, which has been factored into earnings per share forecasts but does not alter its overall earnings outlook.

The most recent analyst rating on (JP:4536) stock is a Hold with a Yen1722.00 price target. To see the full list of analyst forecasts on Santen Pharmaceutical Co stock, see the JP:4536 Stock Forecast page.